Millie
your market intelligence analyst
Search Results
Edit Save
125 results
Ovarian Cancer News Today 11/15/2019 12:50
Women who require assisted reproductive technology to become mothers are not more likely to develop ovarian cancer, except for those with endometriosis, a new study suggests. The study, “Assisted reproductive technology treatment and risk of ovarian cancer—a nationwide population-based cohort study,” was published in the journal Human Reproduction. Assisted reproductive technology (ART), like in vitro […]. .
Ovarian Cancer News Today 11/11/2019 15:05
Commonly used in primary healthcare, blood tests for CA125 may help diagnose ovarian cancer and other types of cancer, particularly in older individuals, new research suggests. The findings were described in two presentations at the recent 2019 National Cancer Research Institute (NCRI) Conference in Glasgow, UK. The sessions were titled, “The predictive value of CA125 […]. .
Ovarian Cancer News Today 11/06/2019 12:54
Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings support the initiation of a Phase 1 trial testing the compound early next year, investigators said. Researchers from Syros presented the findings in a poster […]. .
Ovarian Cancer News Today 11/04/2019 12:47
OTL38, a tumor-specific fluorescent compound that “lights up” ovarian tumor tissue during surgery, helped doctors to detect and remove cancer cells that would otherwise be missed, final results of a Phase 2 study show. The study, “A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer,” […]. .
Ovarian Cancer News Today 11/01/2019 12:52
Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian cancer, a new study found. These results suggest that Zejula could increase quality of life in addition to slowing cancer growth. The study, “Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus […]. .
Ovarian Cancer News Today 10/30/2019 13:03
Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase 3 study show. This maintenance therapy was given after partial or complete response to first-line platinum-based chemotherapy. The benefits were, however, even more pronounced in women […]. .
Ovarian Cancer News Today 10/28/2019 12:52
Women with ovarian cancer who are partially sensitive to platinum-based chemotherapy may benefit from a new combination therapy — but safety concerns need to be addressed first, a study suggests. The new study proposes a combination of trabectedin and bevacizumab with platinum-based chemotherapy for these patients, whose disease relapsed within six to 12 months after treatment. […]. .
Ovarian Cancer News Today 10/25/2019 11:17
The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a late-line treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have tumors defective in DNA repair, a status termed "homologous recombination deficiency" (HRD), and have received at least three prior courses of chemotherapy.
Ovarian Cancer News Today 10/23/2019 13:57
A newly developed imaging approach that combines laser microscopy with computational analysis may make it easier to spot ovarian cancer cells that have spread to other organs, called metastasis, a study found. The new technique was described in a paper, titled “Two-photon images reveal unique texture features for label-free identification of ovarian cancer peritoneal metastases,” […]. .
Ovarian Cancer News Today 10/18/2019 09:04
The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube and peritoneal cancer who responded to platinum-based chemotherapy, regardless of their BRCA status or previous lines of treatment.
Ovarian Cancer News Today 10/09/2019 11:49
The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track designation is given to investigational compounds that show considerable potential in treating serious conditions for which available treatments still fall short. This designation is meant […]. .
Ovarian Cancer News Today 10/07/2019 13:32
ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to exploratory analysis on the data of the FORWARD I Phase 3 trial (NCT02631876).
Ovarian Cancer News Today 10/02/2019 10:15
Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 (DKK1) protein, or specific mutations in the Wnt signaling pathway, according to results of a Phase 2 clinical trial.
Ovarian Cancer News Today 09/30/2019 11:12
Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer, a new study suggests. The study, “Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study,” was published in the journal Gynecologic Oncology. Non-epithelial […]. .
Ovarian Cancer News Today 09/27/2019 12:36
Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of the patients’ response to prior treatment with platinum-based chemotherapy agents. The analysis will be presented at the European Society for Medical Oncology (ESMO) Congress 2019, […]. .
Ovarian Cancer News Today 09/25/2019 10:32
Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore (UMB). The agreement gives Spherix rights to a patent application, now under consideration by the U.S. Patents Trademark Office. Spherix has until early December to execute […]. .
Ovarian Cancer News Today 09/23/2019 12:46
On Sept. 20, the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) and the European Society of Gynaecological Oncology (ESGO) presented the first World Gynecologic Oncology Day (World GO Day). Spearheaded by ENGAGe, the initiative, set to occur annually, aims to promote collaboration among patient groups, strengthen local advocacy activities, and provide an engagement platform. […]. .
Ovarian Cancer News Today 09/20/2019 11:32
For the first time, scientists have found evidence that pain is an independent marker for overall survival in recurrent ovarian cancer, with women with pain living for significantly less time after their diagnosis than those without pain. The survival toll is particularly high for patients with pain despite receiving pain medication, who have seven months […]. .

Food and Human Nutrition

Business Issues

Companies - Public

Companies - Venture Funded

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Products - Animal

Products - Plant

Political Entities

Strategic Scenarios

Sources

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications